Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 11/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104432 | 0.91 | CTSS (0.46) | CTSSSSTR5HRH1HTR2BKDM4E | |
| SCHEMBL3104482 | 0.91 | SSTR5 (0.48) | CTSSSSTR5HRH1HTR2BKDM4E | |
| SCHEMBL3097994 | 0.90 | CTSS (0.51) | CTSSSSTR5ALDH1A1KDM4EKCNH2 | |
| SCHEMBL3104418 | 0.90 | CTSS (0.46) | CTSSSSTR5HRH1HTR2BALDH1A1 | |
| SCHEMBL3104533 | 0.90 | CTSS (0.46) | CTSSSSTR5HRH1HTR2B | |
| SCHEMBL3081943 | 0.90 | CTSS (0.46) | CTSSSSTR5HRH1HTR2BKDM4E | |
| SCHEMBL3080430 | 0.90 | CTSS (0.48) | CTSSSSTR5HRH1HTR2B | |
| SCHEMBL3098654 | 0.89 | CTSS (0.48) | CTSSSSTR5HRH1HTR2BALDH1A1 | |
| SCHEMBL3104293 | 0.89 | NPC1 (0.45) | CTSSSSTR5HRH1HTR2BALDH1A1 | |
| SCHEMBL3094207 | 0.89 | SSTR5 (0.47) | CTSSSSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | claimed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | claimed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | claimed |
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | disclosed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | SSTR5, SSTR3, SSTR1 | CTSS 2371/4885SSTR5 1/4885HRH1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.